Английская Википедия:HU-243
Шаблон:Short description Шаблон:Drugbox
HU-243 (AM-4056) is a synthetic cannabinoid drug that is a single enantiomer of the hydrogenated derivative of the commonly used reference agonist HU-210. It is a methylene homologue of canbisol. It is a potent agonist at both the CB1 and CB2 receptors, with a binding affinity of 0.041 nM at the CB1 receptor, making it marginally more potent than HU-210, which had an affinity of 0.061 nM in the same assay.[1]
Legal status
HU-243 is not listed in the schedules set out by the United Nations Single Convention on Narcotic Drugs from 1961 nor their Convention on Psychotropic Substances from 1971,[2] so the signatory countries to these international drug control treaties are not required by said treaties to control HU-243.
United States
HU-243 is not listed in the list of scheduled controlled substances in the USA.[3] It is therefore not scheduled at the federal level in the United States, but it is possible that HU-243 could legally be considered an analog of THC (which is one of the substances controlled in Schedule I as "tetrahydrocannabinols") or another synthetic Schedule I cannabinoids such as CP-47,497, and therefore sales or possession could potentially be prosecuted under the Federal Analogue Act.[4]
Florida
HU-243 is a Schedule I controlled substance, categorized as a hallucinogen, making it illegal to buy, sell, or possess in the state of Florida without a license.[5] Шаблон:Cquote
Vermont
Effective January 1, 2016, HU-243 is probably (a little doubt arises due to apparent mistaken naming) a regulated drug in Vermont designated as a "Hallucinogenic Drug."[6] Шаблон:Quote
The above chemical name ("3-dimethylheptyl-11-hydroxyhexahydrocannabinol") and common ("canbisol") or trade names ("nabidrox") are not the same chemical as HU-243. They identify Canbisol, of which HU-243 is a methylene homologue.
See also
References
